FDA approves Biofrontera's Ameluz for superficial basal cell carcinoma
Tweet Send to a Friend
Biofrontera Inc. (NASDAQ: BFRI) announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


